Biomedical subjects

Wm Philip Werschler

Publications and source records attributed to Wm Philip Werschler.

4 recordsLinked to original sources

PubMed2004

Matching patients with therapy.

Multiple options are available for the treatment of actinic keratosis (AK). Each therapy has its own idiosyncrasies and risks, and not every modality is appropriate for every patient. Physician experience and clinical factors such as patient demographics, concerns, reason for the office visit, and lifestyle, as well as the pros and cons of each treatment modality, must be considered when developing customized rational treatment programs.

Combined Modality Therapy↗

PubMed2004

Treatment options in the management of actinic keratosis.

Successful treatment of actinic keratosis (AK) requires an understanding of available treatments and matching those treatments with each patient's disease severity, lifestyle, insurance coverage, and primary reason for the physician visit. Cryotherapy and other destructive strategies are optimal for hypertrophic and clearly delineated lesions, but they may not address subclinical lesions and are associated with risk of scarring, infection, and pigmentary changes. Topical therapies such as the fluorouracil creams are appropriate for treating large regions of affected skin but are associated with application-site irritation. A combination of destructive and topical approaches may benefit patients with multiple lesion pathologies.

Combined Modality Therapy↗

PubMed2004

Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule.

Several formulations and concentrations of topical fluorouracil have received US Food and Drug Administration (FDA) approval for the treatment of actinic keratosis (AK). The most commonly used are the fluorouracil 5% and 0.5% creams. In clinical trials, these formulations have demonstrated a marked ability to partially and completely eradicate AK lesions. Application site irritation, erythema, and burning are common side effects of both formulations, but comparative data suggest that the fluorouracil 0.5% cream is more cost-effective and may be safer, more tolerable, and as efficacious as fluorouracil 5% cream.

Administration, Cutaneous↗

PubMedDate not supplied

Longevity of effects of injectable products for soft-tissue augmentation.

With the growing number of injectable products for soft-tissue augmentation, non-surgical total facial restoration is within reach. Nevertheless, the ideal injectable product has yet to be developed; at present different approaches are required for different soft-tissue deficits. Products have previously been categorized as either temporary (requiring frequent touch-up treatments) or permanent (associated with possible long-term complications and results that do not co-exist harmoniously with the aging face). Although this dichotomy remains, longer-lasting or "semi-permanent" products are beginning to emerge. There has long been a void in the availability of products that can effectively rejuvenate the face for between 2 and 5 years. This time period would allow the patient to correct the continuing signs of aging with re-treatment at intervals that are tolerable from both a financial and time-management perspective.

Animals↗